Contact this trialFirst, we need to learn more about you.
Alkylating agent
Carboplatin +1 More for Ovarian Neoplasms
Recruiting1 awardPhase 3
Anchorage, Alaska
This trial found that adding veliparib to standard platinum-based chemotherapy and continuing it as maintenance therapy did not prolong PFS in patients with advanced BRCA-mutated ovarian cancer.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service